Formation of enzymatic/redox-switching nanogates on mesoporous silica nanoparticles for anticancer drug delivery

被引：43

作者：

Luo, Wei ^{[1
,2
]}

Xu, Xin ^{[1
,2
]}

Zhou, Bingjie ^{[1
,2
]}

He, Peixin ^{[3
]}

Li, Yulin ^{[1
,2
]}

Liu, Changsheng ^{[1
,2
]}

机构：

[1] East China Univ Sci & Technol, Minist Educ, State Key Lab Bioreactor Engn, Key Lab Ultrafine Mat, Shanghai 200237, Peoples R China

[2] East China Univ Sci & Technol, Minist Educ, Engn Res Ctr Biomed Mat, Shanghai 200237, Peoples R China

[3] Hubei Univ, Coll Chem & Chem Engn, Key Lab Green Preparat & Applicat Funct Mat, Minist Of Educ, Wuhan 430062, Peoples R China

来源：

MATERIALS SCIENCE AND ENGINEERING C-MATERIALS FOR BIOLOGICAL APPLICATIONS | 2019年 / 100卷

基金：

中国国家自然科学基金;

关键词：

Mesoporous nanoparticles; Gelatin; MMP; 2; cleavable; Nanogate; Anticancer drug delivery; DOXORUBICIN; NANOGELS; CANCER; RELEASE; PACLITAXEL; HYDROGEL; THERAPY; MICELLE; CELLS;

D O I：

10.1016/j.msec.2019.03.028

中图分类号：

TB3 [工程材料学]; R318.08 [生物材料学];

学科分类号：

0805 ; 080501 ; 080502 ;

摘要：

In this study, we demonstrate a simple approach to developing mesoporous nanohybrids via a process of preloading of an anticancer drug (doxorubicin, DOX) into mesoporous silica nanoparticles (MSN), followed by assembly with a kind of naturally-derived polymer (gelatin, cleavable by matrix metalloproteinase 2 overexpressed by tumor). The gelatin shell is then in situ crosslinked by degradable N,N'-bis(acryloyl)cystamine (BAC) to form enzymatic and redox switchable nanogates on the mesoporous nanoparticles. The nanohybrids displayed pH/redox/enzymatic sensitivity in DOX release under conditions mimicking tumor microenvironments. The nanocarriers can be effectively taken up by A549 cells (a carcinomic human alveolar basal epithelial cell line), resulting in a high DOX intracellular accumulation and an improved anticancer cytotoxicity when compared with free DOX, suggesting their potential as a nanoplatform for therapeutic delivery.

引用

页码：855 / 861

页数：7

共 40 条

[1] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].